Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States

References

• Wakelee H, Kelly K, Edelman MJ. 50 Years of progress in the systemic therapy of non-small cell lung cancer [Historical Article Research Support, Non-U.S. Gov’t Review Video-Audio Media]. Am Soc Clin Oncol Edu. 2014;(34):177–189.
   Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S]. J Clin Oncol. 2008;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. J Clin Oncol. 2009;27(8):1227–1234.
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy [Research Support, Non-U.S. Gov’t Research Support, U.S. Gov’t, P.H.] Science. 2004;304(5676):1497–1500.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Lancet Oncol. 2010;11(6):521–529.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [Clinical Trial Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. J Clin Oncol. 2004;22(9):1589–1597.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [Clinical Trial Comparative Study Multicenter Study Randomized Controlled Trial]. J Clin Oncol. 2000;18(10):2095–2103.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer [Clinical Trial Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. N Engl J Med. 2005;353(2):123–132.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. N Engl J Med. 2015;373(17):1627–1639.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. N Engl J Med. 2015;373(2):123–135.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial]. N Engl J Med. 2016;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study [Clinical Trial, Phase II Multicenter Study Randomized Controlled Trial]. Lancet Oncol. 2016;17(11):1497–1508.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurre nt non-small-cell lung cancer [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Comment]. N Engl J Med. 2017;376(25):2415–2426.
   Google Scholar
• Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092.
   PubMed Web of Science ®Google Scholar
• Akerley W. Biomarker-based treatment selection in non-small cell lung cancer. J Natl Compr Canc Netw. 2017;15(5S):689–691.
   PubMed Web of Science ®Google Scholar
• Kris M, Johnson B, Kwiatkowski D, et al. Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). J Clin Oncol. 2011;29(15_suppl):CRA7506–CRA7506.
   Google Scholar
• FDA. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 2017; [cited 2020 Dec 9]. Available from: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm.
   Google Scholar
• Yang S, Imbens GW, Cui Z, et al. Propensity score matching and subclassification in observational studies with multi-level treatments. Biom. 2016;72(4):1055–1065.
   Web of Science ®Google Scholar
• NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-small cell lung cancer, verson 8.2017. 2017; [cited 2017 Aug 31]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
   Google Scholar
• FDA updates highlighting the latest cancer treatments. Oncology Times. 2019;41(5):34–36.
   Google Scholar
• Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Ann Oncol. 2015;26(4):724–730.
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665–673.
   PubMed Web of Science ®Google Scholar
• Wang Q, Huang H, Zeng X, et al. Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials. PeerJ. 2016;4:e2550.
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. Lancet. 2009;374(9699):1432–1440.
   PubMed Web of Science ®Google Scholar
• Mubarak N, Gaafar R, Shehata S, et al. A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer [Clinical Trial, Phase II Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. BMC Cancer. 2012;12:423.
   PubMed Web of Science ®Google Scholar